BRIEF published on 12/17/2025 at 07:35, 10 months 25 days ago Sanofi Releases Q4 2025 Aide Mémoire Sanofi Financial Modeling Aide Mémoire Q4 2025 Forward-Looking
BRIEF published on 12/17/2025 at 07:35, 10 months 25 days ago Sanofi publishes the document "Q4 2025 Quick Reference Guide" Financial Results Investors Sanofi Q4 2025 Modeling
BRIEF published on 12/17/2025 at 07:35, 10 months 25 days ago Sanofi publie le document « Q4 2025 Aide mémoire » Résultats Financiers Investisseurs Sanofi Modélisation Q4 2025
PRESS RELEASE published on 12/17/2025 at 07:30, 10 months 25 days ago Press release: Availability of the Q4 2025 Aide memoire Sanofi announces availability of Q4 2025 Aide memoire on the company's website for financial modeling purposes. Q4 2025 results to be published on January 29, 2026 Sanofi Results Aide Mémoire Financial Modelling Q4 2025
PRESS RELEASE published on 12/17/2025 at 07:30, 10 months 25 days ago Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire » Sanofi annonce la mise en ligne du document 'Q4 2025 Aide mémoire' pour assister la communauté financière dans la modélisation des résultats trimestriels Communication Financière Résultats Trimestriels Sanofi Document Q4 2025
BRIEF published on 12/15/2025 at 07:10, 10 months 27 days ago Sanofi: PERSEUS study results on tolebrutinib disappointing Study Results Multiple Sclerosis Sanofi Tolebrutinib PERSEUS Study
BRIEF published on 12/15/2025 at 07:10, 10 months 27 days ago Sanofi Halts Pursuit of Regulatory Registration for Tolebrutinib in PPMS Multiple Sclerosis Tolebrutinib PPMS Trial PERSEUS Study Sanofi R&D
BRIEF published on 12/15/2025 at 07:10, 10 months 27 days ago Sanofi renonce à l'autorisation de mise sur le marché du tolebrutinib dans le traitement de la SEP progressive primaire Sclérose En Plaques Tolebrutinib Essai PPMS Étude PERSEUS Recherche Et Développement Chez Sanofi
BRIEF published on 12/15/2025 at 07:10, 10 months 27 days ago Sanofi : résultats de l'étude PERSEUS sur le tolébrutinib décevants Sclérose En Plaques Sanofi Tolebrutinib Étude PERSEUS Résultats D'étude
BRIEF published on 12/15/2025 at 07:05, 10 months 27 days ago Sanofi's Tolebrutinib Regulatory Submission Delayed FDA Multiple Sclerosis Sanofi Tolebrutinib Regulatory Delay
Published on 11/11/2026 at 03:30, 4 hours 40 minutes ago CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
Published on 11/11/2026 at 00:40, 7 hours 30 minutes ago Upgraded Tunkillia MRE Validates Optimised Scoping Study
Published on 11/10/2026 at 23:30, 8 hours 40 minutes ago CCL Industries Announces 2026 Third Quarter Results
Published on 11/10/2026 at 23:00, 9 hours 10 minutes ago Vanta Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 9 hours 10 minutes ago Battery X Metals Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/11/2026 at 08:05, 5 minutes ago BLACKYAK Wins Grand Prix at ISPO Amsterdam 2026, A Testament to Its Mountain-Driven Innovation
Published on 11/11/2026 at 08:05, 5 minutes ago Richmond Hill Resources PLC: Sakoose Drilling Underway - First Hole Completed
Published on 11/11/2026 at 08:00, 10 minutes ago Einhell grows in the first nine months of 2026 and strengthens its financial position
Published on 11/11/2026 at 07:30, 40 minutes ago GESCO reports significant increase in earnings in the first nine months and shows stable business performance in a challenging market environment
Published on 11/10/2026 at 18:00, 14 hours 10 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 14 hours 25 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 14 hours 35 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 14 hours 38 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
